Novo Nordisk says trial data show an oral formulation of its GLP-1 analogue semaglutide provided superior HbA1c and weight reductions versus placebo in people with type II diabetes and renal impairment.
More From BioPortfolio on "Novo’s oral semaglutide hits targets in diabetics with renal impairment"